BioSpace News Archive

Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than 30 compounds including gene therapies for rare diseases

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies

The Company has Surpassed its Previous Monthly Record, of $19,062.25 in E-Commerce Sales, Posted During April 2020

Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021

Allogene Therapeutics, Inc., announced the commencement of an underwritten public offering of $450.0 million of shares of its common stock.

First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly’s collaboration with AbCellera

Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 3:00 p.m. ET.

ChromaDex Corp. announced it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide in Human Health and Disease: The State of the Science on Nutrition Interventions” tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted by the American Society for Nutrition.

Invacare Corporation entered into separate, privately negotiated agreements with certain holders of its 5.0% Convertible Senior Notes due 2021 and certain holders of its 4.5% Convertible Senior Notes due 2022 to exchange approximately $32.9 million in aggregate principal amount of 2021 Notes and $38.5 million in aggregate principal amount of 2022 Notes...

Antibe Therapeutics Inc. is pleased to announce that its lead drug, ATB-346, met the primary endpoint in the Phase 2B dose-ranging, efficacy study.